Savara amends Hercules loan; adds $75M drawdown tied to FDA approval of MOLBREEVI

Savara Inc

Amends $105M loan agreement; new $45M and $30M tranches available upon FDA approval of MOLBREEVI for aPAP.
First Post-Approval Tranche of $45M must be drawn within 120 days or by June 30, 2027.
Second $30M tranche available after first tranche drawn or expired, same deadline.
Financial covenant compliance dates extended: unrestricted cash to Apr 2027, revenue covenant to Sep 2027 if market cap low.
Lenders granted first-priority security interest in IP, converting to negative pledge if RTW Purchase Agreement terminated and $50M+ cash held.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Savara Inc amended First Amendment with lenders party thereto and Hercules Capital, Inc., as administrative agent and collateral agent valued at up to an aggregate of $105 million of term loans (effective 2026-01-26).

Action: amendment
Agreement: credit facility
Counterparty: lenders party thereto and Hercules Capital, Inc., as administrative agent and collateral agent
Value: up to an aggregate of $105 million of term loans
Effective: 2026-01-26

Exact text from the filing

On January 26, 2026, Savara Inc. (the “Company”) entered into a First Amendment (the “First Amendment”) to the Loan and Security Agreement, dated March 26, 2025 (the “Loan Agreement”), with the lenders party thereto (the “Lenders”) and Hercules Capital, Inc., as administrative agent and collateral agent.

View on SEC.gov

317 material agreements filed in the last 30 days. Browse all material agreements →

Savara Inc filing history →

Source: SEC EDGAR

accession 0001193125-26-023378

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.